164 related articles for article (PubMed ID: 37162105)
1. Less necessity of adjuvant S-1 treatment in non-monarchE-eligible patients.
Yu M; Takada M; Yamada H; Fujimoto H; Sakakibara J; Yamamoto H; Nagashima T; Ohtsuka M
Cancer Med; 2023 Jun; 12(12):13193-13203. PubMed ID: 37162105
[TBL] [Abstract][Full Text] [Related]
2. Treatment With Adjuvant Abemaciclib Plus Endocrine Therapy in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy: A Prespecified Analysis of the monarchE Randomized Clinical Trial.
Martin M; Hegg R; Kim SB; Schenker M; Grecea D; Garcia-Saenz JA; Papazisis K; Ouyang Q; Lacko A; Oksuzoglu B; Reeves J; Okera M; Testa L; Shimizu C; Denduluri N; Adamchuk H; Dakhil S; Wei R; Forrester T; Fernandez MM; Zimmermann A; Headley D; Johnston SRD
JAMA Oncol; 2022 Aug; 8(8):1190-1194. PubMed ID: 35653145
[TBL] [Abstract][Full Text] [Related]
3. Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE).
Johnston SRD; Harbeck N; Hegg R; Toi M; Martin M; Shao ZM; Zhang QY; Martinez Rodriguez JL; Campone M; Hamilton E; Sohn J; Guarneri V; Okada M; Boyle F; Neven P; Cortés J; Huober J; Wardley A; Tolaney SM; Cicin I; Smith IC; Frenzel M; Headley D; Wei R; San Antonio B; Hulstijn M; Cox J; O'Shaughnessy J; Rastogi P;
J Clin Oncol; 2020 Dec; 38(34):3987-3998. PubMed ID: 32954927
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study.
Harbeck N; Rastogi P; Martin M; Tolaney SM; Shao ZM; Fasching PA; Huang CS; Jaliffe GG; Tryakin A; Goetz MP; Rugo HS; Senkus E; Testa L; Andersson M; Tamura K; Del Mastro L; Steger GG; Kreipe H; Hegg R; Sohn J; Guarneri V; Cortés J; Hamilton E; André V; Wei R; Barriga S; Sherwood S; Forrester T; Munoz M; Shahir A; San Antonio B; Nabinger SC; Toi M; Johnston SRD; O'Shaughnessy J;
Ann Oncol; 2021 Dec; 32(12):1571-1581. PubMed ID: 34656740
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center.
Dannehl D; Volmer LL; Weiss M; Matovina S; Grischke EM; Oberlechner E; Seller A; Walter CB; Hahn M; Engler T; Brucker SY; Hartkopf AD
J Pers Med; 2022 Mar; 12(3):. PubMed ID: 35330381
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1.
Toi M; Boyle F; Im YH; Reinisch M; Molthrop D; Jiang Z; Wei R; Sapunar F; Grimes BR; Nabinger SC; Johnston SRD
Oncologist; 2023 Jan; 28(1):e77-e81. PubMed ID: 36342342
[TBL] [Abstract][Full Text] [Related]
7. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study.
Rugo HS; O'Shaughnessy J; Boyle F; Toi M; Broom R; Blancas I; Gumus M; Yamashita T; Im YH; Rastogi P; Zagouri F; Song C; Campone M; San Antonio B; Shahir A; Hulstijn M; Brown J; Zimmermann A; Wei R; Johnston SRD; Reinisch M; Tolaney SM;
Ann Oncol; 2022 Jun; 33(6):616-627. PubMed ID: 35337972
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry.
Frevert ML; Dannehl D; Jansen L; Hermann S; Schäffler H; Huwer S; Janni W; Juhasz-Böss I; Hartkopf AD; Taran FA
Arch Gynecol Obstet; 2024 Mar; ():. PubMed ID: 38472501
[TBL] [Abstract][Full Text] [Related]
9. [Decision-Making Regarding Adjuvant Therapy for Hormone Receptor-Positive, HER2-Negative Early Breast Cancer].
Waraya M; Inukai M; Kojima K; Oshida S; Habiro T; Ishii K; Hayashi K
Gan To Kagaku Ryoho; 2023 Feb; 50(2):230-232. PubMed ID: 36807181
[TBL] [Abstract][Full Text] [Related]
10. SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment.
Abdel-Fatah TMA; Broom RJ; Lu J; Moseley PM; Huang B; Li L; Liu S; Chen L; Ma RZ; Cao W; Wang X; Li Y; Perry JK; Aleskandarany M; Nolan CC; Rakha EA; Lobie PE; Chan SYT; Ellis IO; Hwang LA; Lane DP; Green AR; Liu DX
Br J Cancer; 2019 Apr; 120(7):728-745. PubMed ID: 30816325
[TBL] [Abstract][Full Text] [Related]
11. Systemic therapy for treating locoregional recurrence in women with breast cancer.
Rauschecker H; Clarke M; Gatzemeier W; Recht A
Cochrane Database Syst Rev; 2001; 2001(4):CD002195. PubMed ID: 11687148
[TBL] [Abstract][Full Text] [Related]
12. [Clinical characteristics and prognosis of patients with ipsilateral breast tumor recurrence after breast conservation therapy].
Sun GY; Wang SL; Tang Y; Jin J; Song YW; Liu YP; Wang WH; Fang H; Chen SY; Ren H; Liu XF; Yu ZH; Li YX
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):352-358. PubMed ID: 29860762
[No Abstract] [Full Text] [Related]
13. Ki67 in Breast Cancer Assay: An Ad Hoc Testing Recommendation from the Canadian Association of Pathologists Task Force.
Faragalla H; Plotkin A; Barnes P; Lu FI; Kos Z; Mulligan AM; Bane A; Nofech Mozes S
Curr Oncol; 2023 Mar; 30(3):3079-3090. PubMed ID: 36975446
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of a 55-gene classifier as a prognostic biomarker for adjuvant chemotherapy in stage III colon cancer patients.
Oki E; Shinto E; Shimokawa M; Yamaguchi S; Ishiguro M; Hasegawa S; Takii Y; Ishida H; Kusumoto T; Morita M; Tomita N; Shiozawa M; Tanaka M; Ozawa H; Hashiguchi Y; Ohnuma S; Tada S; Matsushima T; Hase K
BMC Cancer; 2021 Dec; 21(1):1332. PubMed ID: 34906120
[TBL] [Abstract][Full Text] [Related]
15. Abemaciclib in Combination with Endocrine Therapy for Adjuvant Treatment of Hormone Receptor-Positive, HER2-Negative, Node-Positive Early Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Orozco Leal G; Armstrong N; Kernohan A; Ahmadu C; Coughlan D; McDermott K; Duffy S; O'Meara S; Robinson T; Vale L; Kleijnen J
Pharmacoeconomics; 2023 Jul; 41(7):741-750. PubMed ID: 36952138
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2-, node-positive, high-risk early breast cancer.
Paluch-Shimon S; Neven P; Huober J; Cicin I; Goetz MP; Shimizu C; Huang CS; Lueck HJ; Beith J; Tokunaga E; Contreras JR; de Sant'Ana RO; Wei R; Shahir A; Nabinger SC; Forrester T; Johnston SRD; Harbeck N
Ther Adv Med Oncol; 2023; 15():17588359231151840. PubMed ID: 36756142
[TBL] [Abstract][Full Text] [Related]
17. Genomic predictor of residual risk of recurrence after adjuvant chemotherapy and endocrine therapy in high risk estrogen receptor-positive breast cancers.
Khan SS; Karn T; Symmans WF; Rody A; Müller V; Holtrich U; Becker S; Pusztai L; Hatzis C
Breast Cancer Res Treat; 2015 Feb; 149(3):789-97. PubMed ID: 25651779
[TBL] [Abstract][Full Text] [Related]
18. Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor.
Linderholm B; Bergqvist J; Hellborg H; Johansson U; Linderholm M; von Schoultz E; Elmberger G; Skoog L; Bergh J
Med Oncol; 2009 Dec; 26(4):480-90. PubMed ID: 19130322
[TBL] [Abstract][Full Text] [Related]
19. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
20. Abemaciclib Reigns Over Breast Cancer in MonarchE.
Cancer Discov; 2020 Dec; 10(12):OF3. PubMed ID: 33051239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
